Patients with no psoriasis risk allele may still benefit from ustekinumab

But ethnicity is an important unknown factor in response rates, say researchers

Being positive for the psoriasis risk allele is associated with a better response to ustekinumab therapy in patients with plaque psoriasis — but those with negative findings also do well, a meta-analysis shows.